Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genome-wide association study of autopsy-confirmed Multiple System Atrophy identifies common variants near ZIC1 and ZIC4

Franziska Hopfner, Anja K. Tietz, Viktoria Ruf, Owen A. Ross, View ORCID ProfileShunsuke Koga, View ORCID ProfileDennis Dickson, View ORCID ProfileAdriano Aguzzi, Johannes Attems, Thomas Beach, Allison Beller, Vivianna van Deerlin, Paula Desplats, Günther Deuschl, Charles Duyckaerts, David Ellinghaus, Valentin Evsyukov, Margaret Ellen Flanagan, Andre Franke, Matthew P. Frosch, Marla Gearing, Ellen Gelpi, Bernardino Ghetti, Jonathan D. Glass, Lea T. Grinberg, View ORCID ProfileGlenda Halliday, View ORCID ProfileIngo Helbig, Matthias Höllerhage, Inge Huitinga, David John Irwin, Dirk C. Keene, Gabor G. Kovacs, Edward B. Lee, Johannes Levin, Maria J. Martí, Ian Mackenzie, Ian McKeith, Catriona Mclean, Brit Mollenhauer, Manuela Neumann, Kathy L. Newell, View ORCID ProfileAlex Pantelyat, Manuela Pendziwiat, Annette Peters, Laura Molina Porcel, Alberto Rabano, Radoslav Matěj, Alex Rajput, Ali Rajput, Regina Reimann, View ORCID ProfileWilliam K. Scott, William Seeley, Sashika Selvackadunco, Tanya Simuni, Christine Stadelmann, Per Svenningsson, Alan Thomas, Claudia Trenkwalder, Claire Troakes, John Q. Trojanowski, View ORCID ProfileCharles L. White, Tao Xie, Teresa Ximelis, Justo Yebenes, the Alzheimer’s Disease Genetics Consortium, Ulrich Müller, Gerard D. Schellenberg, Jochen Herms, Gregor Kuhlenbäumer, View ORCID ProfileGünter Höglinger
doi: https://doi.org/10.1101/2021.11.11.21265915
Franziska Hopfner
1Department of Neurology Hannover Medical School Hanover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: franziska.hopfner@gmx.de
Anja K. Tietz
2Department of Neurology, Kiel University, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viktoria Ruf
3Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, 81377 Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Owen A. Ross
4Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA
5Department of Clinical Genomics, Mayo Clinic, Jacksonville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunsuke Koga
6Department of Neuroscience (Neuropathology), Mayo Clinic, Jacksonville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shunsuke Koga
Dennis Dickson
6Department of Neuroscience (Neuropathology), Mayo Clinic, Jacksonville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dennis Dickson
Adriano Aguzzi
7Institute of Neuropathology, University Hospital Zürich, Zürich, CH-8091, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adriano Aguzzi
Johannes Attems
8Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE4 5PL UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Beach
9Banner Sun Health Research Institute, Sun City, Arizona, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison Beller
10Department of Pathology, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivianna van Deerlin
11Department of Pathology and Laboratory Medicine, Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Desplats
12Department of Neurosciences, School of Medicine University of California San Diego La Jolla California USA
13Department of Pathology, School of Medicine University of California San Diego La Jolla California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Günther Deuschl
2Department of Neurology, Kiel University, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Duyckaerts
14Institut du Cerveau, UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Inserm U1127 DMU Neurosciences, Paris, France
15Brainbank NeuroCEB Neuropathology Network: Plateforme de Ressources Biologiques, Hôpital de La Pitié-Salpêtrière, Bâtiment Roger Baillet, 47-83 boulevard de l’Hôpital, 75651, Paris Cedex 13, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ellinghaus
16Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentin Evsyukov
1Department of Neurology Hannover Medical School Hanover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Ellen Flanagan
17Mesulam Center for Cognitive Neurology and Alzheimer’s Disease Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
18Department of Pathology, Northwestern University, Chicago, IL 60611, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre Franke
16Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew P. Frosch
19Department of Neurology, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA and Harvard Medical School, Boston, Massachusetts, USA
20Department of Pathology, Massachusetts General Hospitalgrid.32224.35, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marla Gearing
21Departments of Pathology and Laboratory Medicine and Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen Gelpi
22Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria
23Medical University of Vienna, Austrian Reference Center for Human Prion Diseases (OERPE), 1090 Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernardino Ghetti
24Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan D. Glass
25Department of Neurology, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lea T. Grinberg
26Memory and Aging Center, Weill Institute for Neurosciences, Dept. of Neurology, University of California San Francisco, CA, USA; Global Health Institute, University of California, San Francisco, CA, USA
27Department of Pathology, University of California, San Francisco, CA, USA
28Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenda Halliday
29The University of Sydney, School of Medical Sciences, and Brain & Mind Centre, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Glenda Halliday
Ingo Helbig
30Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
31Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
32Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
33The Epilepsy NeuroGenetics Initiative (ENGIN), Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
34Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ingo Helbig
Matthias Höllerhage
1Department of Neurology Hannover Medical School Hanover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inge Huitinga
35Department of Neuroimmunology, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Brain Plasticity Group, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David John Irwin
36Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk C. Keene
37Department of Pathology, University of Washington, Seattle, WA, 98195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabor G. Kovacs
22Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria
38Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
39Laboratory Medicine Program and Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward B. Lee
40Translational Neuropathology Research Laboratory Perelman School of Medicine Department of Pathology and Laboratory Medicine Philadelphia Pennsylvania USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Levin
41DZNE - German Center for Neurodegenerative Diseases, Munich, Germany
42Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, 81377 Munich, Germany
43Department of Neurology, Ludwig-Maximilians-Universität München, 80539 Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria J. Martí
44Parkinson’s Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic of Barcelona, Spain
45Institut de Neurociències, Maeztu Center, University of Barcelona, Spain
46Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain
47Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Mackenzie
48Department of Pathology, University of British Columbia, Vancouver, BC, Canada and Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian McKeith
49Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catriona Mclean
50Department of Anatomical Pathology, Alfred Health, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brit Mollenhauer
51Paracelsus-Elena-Klinik, Kassel, Germany
52Department of Neurology, University Medical Center Goettingen, Goettingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Neumann
53Molecular Neuropathology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Tübingen, Germany
54Department of Neuropathology, University Hospital of Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy L. Newell
55Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Pantelyat
56Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alex Pantelyat
Manuela Pendziwiat
57Department of Neuropediatrics, Children’s Hospital, University Medical Center Schleswig-Holstein, University of Kiel, Kiel, Germany
58Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Peters
59Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Molina Porcel
60Neurology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Rabano
61Neuropathology Department, CIEN Foundation, Alzheimer’s Centre Queen Sofía Foundation, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Radoslav Matěj
62Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Ruská 87, 100 00, Praha 10, Prague, Czech Republic and Department of Pathology
63Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Rajput
64Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Rajput
65Saskatchewan Movement Disorders Program, Saskatchewan Health Authority/University of Saskatchewan, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regina Reimann
7Institute of Neuropathology, University Hospital Zürich, Zürich, CH-8091, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William K. Scott
66John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William K. Scott
William Seeley
26Memory and Aging Center, Weill Institute for Neurosciences, Dept. of Neurology, University of California San Francisco, CA, USA; Global Health Institute, University of California, San Francisco, CA, USA
27Department of Pathology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sashika Selvackadunco
67Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, SE5 8AF London U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya Simuni
68Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Stadelmann
69Institute for Neuropathology, University Medical Centre Göttingen, Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Svenningsson
70Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Thomas
8Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE4 5PL UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Trenkwalder
51Paracelsus-Elena-Klinik, Kassel, Germany
71Department of Neurosurgery, University Medical Center Goettingen, Goettingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Troakes
67Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, SE5 8AF London U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Q. Trojanowski
72Center for Neurodegenerative Disease Research Perelman School of Medicine Department of Pathology and Laboratory Medicine Philadelphia Pennsylvania USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles L. White
73Pathology, University of Texas Southwestern Medical Center, Dallas, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles L. White
Tao Xie
74Department of Neurology, University of Chicago Medicine, Chicago, IL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Ximelis
75Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justo Yebenes
76Neurological Tissue Bank, Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain. Servicio de Neurología. Hospital Ramón y Cajal de Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
77NIAGADS, The National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site, Alzheimer’s Disease Genetics Consortium (ADGC) NIA grant U01AG032984
Ulrich Müller
78Institute of Human Genetics, JLU-Gießen, Schlangenzahl 14, 35392, Giessen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard D. Schellenberg
11Department of Pathology and Laboratory Medicine, Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jochen Herms
3Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, 81377 Munich, Germany
41DZNE - German Center for Neurodegenerative Diseases, Munich, Germany
42Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Strasse 17, 81377 Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregor Kuhlenbäumer
2Department of Neurology, Kiel University, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Günter Höglinger
1Department of Neurology Hannover Medical School Hanover Germany
41DZNE - German Center for Neurodegenerative Diseases, Munich, Germany
79Zentrum für Systemische Neurowissenschaften, Hannover, Deutschland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Günter Höglinger
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Multiple System Atrophy is a rare neurodegenerative disease with alpha-synuclein aggregation in glial cytoplasmic inclusions and either predominant olivopontocerebellar atrophy or striatonigral degeneration, leading to dysautonomia, parkinsonism, and cerebellar ataxia. One prior genome-wide association study in mainly clinically diagnosed patients with Multiple System Atrophy failed to identify genetic variants predisposing for the disease. Since the clinical diagnosis of Multiple System Atrophy yields a high rate of misdiagnosis when compared to the neuropathological gold standard, we studied common genetic variation in only autopsy-confirmed cases (N = 731) and controls (N = 2,898).

The most strongly disease-associated markers were rs16859966 on chromosome 3 (P = 8.6 × 10−7, odds ratio (OR) = 1.58, [95% confidence interval (CI) = 1.32-1.89]), rs7013955 on chromosome 8 (P = 3.7 × 10−6, OR = 1.8 [1.40-2.31]), and rs116607983 on chromosome 4 (P = 4.0 × 10−6, OR = 2.93 [1.86-4.63]), all of which were supported by at least one additional genotyped and several imputed single nucleotide polymorphisms with P-values below 5 × 10−5. The genes closest to the chromosome 3 locus are ZIC1 and ZIC4 encoding the zinc finger proteins of cerebellum 1 and 4 (ZIC1 and ZIC4).

Since mutations of ZIC1 and ZIC4 and paraneoplastic autoantibodies directed against ZIC4 are associated with severe cerebellar dysfunction, we conducted immunohistochemical analyses in brain tissue of the frontal cortex and the cerebellum from 24 Multiple System Atrophy patients. Strong immunohistochemical expression of ZIC4 was detected in a subset of neurons of the dentate nucleus in all healthy controls and in patients with striatonigral degeneration, whereas ZIC4 positive neurons were significantly reduced in patients with olivopontocerebellar atrophy.

These findings point to a potential ZIC4-mediated vulnerability of neurons in Multiple System Atrophy.

Introduction

Multiple System Atrophy (MSA) is a rapidly progressive rare neurodegenerative disease presenting with variable combinations of dysautonomia, parkinsonism and cerebellar ataxia[10]. Two forms of MSA can be clinically distinguished, characterized by either predominant parkinsonism (MSA-P) or predominant cerebellar symptoms (MSA-C)[12]. Its estimated prevalence is 3.4 to 4.9 cases per 100,000 individuals in the general population, and 7.8 cases per 100,000 in persons older than 40 years[32]. The mean survival time from disease onset is 6 to 10 years [16, 41]. Currently, only limited symptomatic treatments and no disease-modifying therapies are available[28].

The typical symptoms of MSA are caused by the progressive degeneration of neurons in different brain regions, particularly in the substantia nigra, striatum, inferior olivary nucleus, pons and cerebellum, but also other parts of the central nervous systems, emphasizing the multisystem character of MSA [12, 40]. The histological hallmarks in brains of MSA patients are glial cytoplasmic inclusions (GCIs, Papp-Lantos bodies) in oligodendrocytes containing aggregated and misfolded alpha-synuclein[14]. Neuropathologically, two subtypes can be distinguished, one with predominant olivopontocerebellar atrophy (OPCA), the other with mainly striatonigral degeneration (SND)[15, 26]. In addition, a mixed phenotype displaying features of both OPCA and SND is found in the brains of some patients[15, 26].

The pathogenesis of MSA is unclear. MSA is considered as a sporadic disease[11]. Epidemiological studies have investigated the influence of environmental factors in MSA, including exposure to farming-related factors (pesticides, solvents, mycotoxins, dust, fuels, oils, fertilizers, animals) and certain lifestyles (consumption of well water, rural living, diet and physical activity)[8, 23, 39]. Apart from a marginal effect of pesticides, no other environmental factors have been convincingly associated with an increased risk of developing MSA[8, 23, 39].

Hypothesis-driven candidate gene studies have been inconsistent with respect to variants that might be associated with MSA. Associations of MSA with the genes COQ2, SNCA, MAPT, and PRNP have been discussed[7, 20, 21, 29, 31, 33]. One prior genome-wide association study (GWAS) did not identify hits of statistical significance at a genome-wide level, despite the analysis of 918 cases and controls[30]. This GWAS had mainly included clinically diagnosed MSA cases. It needs to be stressed that clinical diagnosis is frequently not accurate in MSA. For example, a recent clinico-pathological study demonstrated a false positive diagnosis at autopsy in 38% of clinically diagnosed MSA patients[17].

In order to avoid inclusion of misdiagnosed patients in the GWAS described here, we only included autopsy-confirmed cases and appropriate ethnicity-matched controls.

Methods

Patient recruitment

Ethical approval had been obtained from all responsible ethics committees. All participants had given written consent.

Neuropathologists at each recruitment site (Supplementary material, Supplementary Table S1) based the definite neuropathological diagnosis of MSA on histopathological criteria taking into account GCIs immunoreactive for alpha-synuclein in characteristic anatomical distribution as defining feature of MSA[37]. Age, gender, disease history (including disease onset and duration) and neuropathological findings were recorded in standardized manner for all cases.

Controls were ethnically matched to cases and either derived from biobanks KORA-gen[42] or popGen[24] (Europe sites) or from North American site (Alzheimer’s Disease Genetics Consortium)[19]. The Alzheimer’s Disease Genetics Consortium assembled and genotyped DNA from subjects enrolled in the 29 NIA-Alzheimer’s Disease Centers located across the USA. For this study, the ADGC provided a subset of mostly clinical, cognitively normal controls. Patients and controls were of North-Western European and African American ancestry.

DNA extraction

We isolated DNA from 30 mg frozen cerebellar cortex using QIAamp DNA Mini Kit (Qiagen, Venlo, Netherlands). DNA extraction was performed at German Center for Neurodegenerative Diseases (DZNE), Munich Germany. DNA was stored at -80 °C until use. DNA concentration was measured using a NanoDrop Spectrophotometer. DNA quality was determined by gel electrophoresis.

Genotyping

All samples were genotyped on Infinium Global Screening Arrays (GSA, Illumina, San Diego, USA). The cases were genotyped at the Institute of Clinical Molecular Biology, Kiel University, Germany. The samples were genotyped in one batch on array version 2.0 for cases and version 1.0 for controls. Genotypes were called using Illumina Genome studio according to the manufacturers instructions using in-house cluster-files.

Quality control and imputation

We used PLINK (v. 1.9) [1] and R (v. 3.6.3)[35] for all analyses. Only variants successfully genotyped in both the patient and the control populations were included in the subsequent analyses. Variants with multi-character allele codes, insertions, deletions, duplicated markers and all A/T and G/C variants were excluded. We excluded all samples discordant between reported and genotypic sex. Missing sex was imputed and samples with ambiguously imputed sex were discarded. After a first step of filtering out samples and variants with call rate of less than 85%, we excluded variants with an individual call rate of less than 98% in a second filtering step. Next, we removed variants with a minor allele frequency (MAF) below 0.01, significant deviation from Hardy-Weinberg equilibrium (HWE; P < 1 × 10−6) in controls or informative missingness (P < 1 × 10−5). Subsequently, we excluded individuals with a variant call rate of less than 98% or an outlying heterozygosity rate (mean ± 3 standard deviations). We used a pruned dataset containing only markers in low linkage-disequilibrium (LD) regions (pairwise r2 < 0.2) to test for duplicated individuals and cryptic relatedness (Pihat > 0.125) using pairwise genome-wide estimates of the proportion of identity by descent. Of each detected sample pair we excluded the individual with a lower call rate. Ethnical outliers were identified by a principal component analysis (PCA) together with the publically available 1000 Genomes data with known ethnicities.[2] Since the study population has genetically a mainly European ancestry, as ascertained by the PCA, we determined a European center and excluded samples more than 1.5 times the maximal European Euclidean distance away from this center. After a first association analysis of genotyped single nucleotide polymorphisms (SNPs) only, we inspected visually the cluster plots of all variants with a P-value below 1 × 10−5 and discarded variants without adequate cluster separation.

Imputation was carried out on the quality assured dataset using the TOPMed Imputation Server, resulting in 271,284,138 available SNPs.[34] Variants were again filtered for MAF and deviation from HWE in controls with the same thresholds as before. Additionally, SNPs with an imputation quality score R2 less than 0.7 were excluded, leaving 8,131,900 variants for analyses. As final step of the quality control procedure, we employed the R package PCAmatchR to ethnically match cases to controls with a 1:4 ratio to overcome possible difficulties with population stratification, leading to 3240 individuals for the analyses.[6]

Association analysis

We used logistic regression to test the additive genetic model of each marker for association with disease status. Following scree plot analysis, we incorporated the first two dimensions of the PCA and sex as covariates. We used a genome-wide significance threshold of P < 5 × 10−8 and the threshold of P < 5 × 10−6 for suggestive association. Conditional analyses including in turn each SNP with a suggestive association as additional covariate were conducted to identify adjacent independent signals. Furthermore, we tested for clumps of correlated SNPs, i.e. to assess how many independent loci had been associated and determined the number of variants supporting the lead SNPs at each locus, i.e. variants that have a P-value < 5 × 10−5, are in LD (r2 ≥ 0.4) and not further than 250 kilobases (kb) away from the respective SNP. Visualization of the results was carried out with R and LocusZoom [27]for regional plots. Variant positions in this manuscript are reported on human genome version 38 (GRCh38/hg38).

Immunohistochemistry on MSA patients’ brain

Formalin-fixed and paraffin embedded (FFPE) tissue from MSA patients and controls without neurological or psychiatric diseases was obtained from the Neurobiobank Munich (NBM; Germany). All autopsy cases of the NBM were collected on the basis of an informed consent according to the guidelines of the ethics commission of the Ludwig-Maximilians-University Munich, Germany (# 345-13). MSA cases had been diagnosed according to established histopatological diagnostic criteria.[26, 37]

For ZIC4 immunohistochemistry, 5 µm thick sections of FFPE tissue of the frontal cortex and the cerebellar hemisphere including the dentate nucleus were prepared. After deparaffinization, heat-induced epitope retrieval was performed in Tris/EDTA, pH 9 at 95 °C for 30 minutes. For blocking of endogenous peroxidase and unspecific protein binding, the sections were incubated with 5% H2O2 in methanol for 20 minutes and I-Block reagent (Applied Biosystems, Waltham, MA, USA) for 15 minutes. Subsequently, ZIC4 primary antibody (rabbit, polyclonal, Merck/Sigma-Aldrich, Darmstadt, Germany) was applied over night at 4 °C at a dilution of 1:100. Signal detection was performed using the DCS ChromoLine DAB kit (DCS, Hamburg, Germany) according to the manufacturer’s instructions. Sections were counterstained for 1 minute with Mayer’s hemalum solution (Waldeck, Münster, Germany).

To determine the fractions of ZIC4 positive neurons of all neurons in the dentate nucleus, stained slides were scanned using a slide scanner (Axio Scan. Z1, Zeiss, Oberkochen, Germany) and visualized using the free ZEN lite software (v 3.3; Zeiss, Oberkochen, Germany). For statistical evaluation of the data, Student’s t-test was used, statistical significance was defined as P < 0.05.

Results

Patient sample

From the initial sample of 731 cases, 13 cases had to be excluded due to insufficient tissue quality. After thorough quality control and filtering, 648 cases and 2,592 controls covering 8,131,900 variants were included in the association analysis (Supplementary Fig. S1). The number of excluded samples and variants in each step of the quality control procedure is shown in Supplementary Tables S2 and S3.

Genotyping

We performed logistic regression incorporating sex and determined the first two dimensions of PCA as covariates using the scree plot method. The genomic inflation factor of λ = 1.01 (unimputed λ = 1.01, Supplementary Fig. S2) indicates that no significant population stratification was present (Fig. 1a). We did not identify any disease-associated variants with a P-value below the genome-wide significance threshold of P < 5 × 10−8, but suggestive associations with P < 5 × 10−6 at ten different loci (Fig. 1b) with the leading SNP at each locus shown in Table 1. Conditional analyses including in turn any SNP with P < 5 × 10−6 excluded the presence of multiple independent signals at each locus. All variants with suggestive associations are listed in Supplementary Table S4. The most noteworthy hits were rs16859966 on chromosome 3 (P = 8.6 × 10−7, odds ratio (OR) = 1.58, [95% confidence interval (CI) = 1.32-1.89]), rs7013955 on chromosome 8 (P = 3.7 × 10−6, OR = 1.8 [1.40-2.31]) and rs116607983 on chromosome 4 (P = 4.0 × 10−6, OR = 2.93 [1.86-4.63]), which were supported by at least one additional genotyped as well as serveal imputed SNPs with P-values below 5 × 10−5 as discovered in the clumping analysis (Table 1). The genes closest to the chromosome 3 locus are the Long Intergenic Non-Protein Coding RNA 2032 (LINC02032) approximately 100 kb downstream and the zinc finger proteins of cerebellum 1 and 4 genes (ZIC1, ZIC4), located roughly 600 kb upstream (Fig. 1c). The top SNP rs7013955 on chromosome 8 maps to the lysyl oxidase-like 2 gene (LOXL2; Fig. 1d). The association signal around SNP rs116607983 on chromosome 4 is located in a region devoid of protein-coding genes approximately 2000 kb to either side (Figure 1e). A fourth locus on chromosome 5 (rs2279135) was also supported by multiple clumped SNPs, but all SNPs including the lead SNP were imputed (Table 1). Several variants clumped at the chromosome 5 locus were located in the ARHGEF37 gene, coding for Rho Guanine Nucleotide Exchange Factor 37 (Fig. 1f). None of the identified SNPs is an expression quantitative trait locus (eQTL) in brain tissues according the Genotype Tissue Expression (GTEx) project.[9] At four of the six remaining loci with variants exhibiting suggestive associations at most two supporting SNPs were present, which were all imputed; in the other two loci no supporting SNPs could be found in the clumping analysis (Table 1, Supplementary Fig. S3). We did not investigate these loci further, because it is unlikely that they represent valid associations. No suggestive associations were detected with previously reported Parkinson’s disease associations from a meta-analysis of 17 datasets from Parkinson’s disease GWAS (Supplementary Table S5).[22]

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1. Top SNPs at each locus with P < 5 × 10−6

Results from association analysis with logistic regression including sex and the first two dimensions of principal component analysis (PCA) as covariates in 648 cases with MSA and 2,898 controls. Only the leading single nucleotide polymorphism (SNP) at each locus with a suggestive association between the disease status and a variant is reported. Supplementary Table S3 lists all suggestive associations. BP = base-pair coordinates according to human reference genome GRCh38, CHR = chromosome, dbSNP = database of single nucleotide polymorphisms, GT = genotyped, IM = imputed, MAF = minor allele frequency.

Fig. 1.
  • Download figure
  • Open in new tab
Fig. 1. Association plots for MSA

(a) QQ (quantile-quantile) plot of association analysis for 8,109,760 variants. (b) Manhattan plot showing –log10 marker-wise P-values of the association analysis against their genomic base-pair position. The red and blue lines indicate the genome-wide significance threshold of 5 × 10−8 and threshold for suggestive associations of 5 × 10−6 respectively. (c) Regional plot for the association between MSA and variants on chromeome 3 in the genomic region from 147.4 to 148.6 Mb. A circle represents a genotyped and a plus symbol an imputed variant. The r2 metric displays the parwise LD between the leading and the resprective variant. The bottom part shows gene postions. (d) Regional plot for associations on chromosome 8 in the genomic resion from 22.7 to 23.9 Mb. (e) Regional plot for associations on chromsome 4 in the genomic region from 32.8 to 34.0 Mb. (f) Regional plot for associations on chromosome 5 in the genomic region from 149.0 to 150.2 Mb.

ZIC4 immunohistochemistry on MSA patients’ brain

ZIC4 and ZIC1 are known to play a critical role in the embryonal development of the cerebellum. Heterozygous deletions comprising the ZIC1 and ZIC4 locus have been associated with the Dandy-Walker malformation, a rare congenital condition characterized by a hypoplastic cerebellar vermis and an enlarged fourth ventricle.[5, 13] In mice, deletions of ZIC1 and ZIC4 lead to a striking phenotype similar to the Dandy-Walker malformation with cerebellar hypoplasia and foliation defects.[5, 13] In addition, paraneoplastic autoantibodies against ZIC4 protein are linked to severe cerebellar dysfunction and degeneration.[3, 4]

Since cerebellar degeneration and corresponding symptoms are also a central hallmark of MSA, we decided to follow up on a potential role of ZIC4 in MSA patient brains by performing immunohistochemical stainings. For ZIC1 no primary antibody was appropriately sensitive and specific on human tissue in our hands. Thus, FFPE tissue of the frontal cortex and the cerebellum of MSA patients (N=10 SND, N=14 OPCA/mixed phenotype) and healthy controls (N=5) were stained with antibodies raised against ZIC4.

Nuclear and cytoplasmic staining of frontal cortex neurons was observed in all brains examined without differences between healthy controls and MSA patients (Fig. 2 a-c). In the cerebellar dentate nucleus, we found strong expression of ZIC4 in a subset of neurons in healthy controls as well as MSA patients with predominant SND (Fig. 2 d,e,g,h). In contrast, MSA patients with mixed subtype or OPCA showed reduced numbers of ZIC4-positive neurons, which were furthermore only weakly stained (Fig. 2 f, i). Quantification of the proportions of ZIC4-positive neurons among all dentate nucleus neurons revealed relatively constant proportions in healthy controls and patients with MSA-SND (33.2% ± 0.0 vs. 32.6% ±0.0), whereas in patients with MSA-OPCA or MSA-mixed phenotype we found significantly lower percentages of ZIC4-positive neurons (15.5% ± 0.1) (Fig. 2 j).

Fig. 2.
  • Download figure
  • Open in new tab
Fig. 2. ZIC4 immunohistochemical staining of MSA patients’ and control brains

Representative ZIC4 immunohistochemical stainings of a control without neurodegenerative diseases (a, d, g) and two MSA patients with SND (striatonigral degeneration) (b, e, h) and a mixed subtype (c, f, i), respectively. (a-c) Nuclear and cytoplasmic expression of ZIC4 was detected in a comparable manner in the frontal cortex of healthy controls and MSA patients (d-i, higher magnification g-i). In the cerebellar dentate nucleus of healthy controls and patients with SND, a constant subset of neurons stained strongly positive for ZIC4, whereas in patients with OPCA (olivopontocerebellar atrophy) or mixed subtypes, only weak staining could be observed and the number of Zic4-positive neurons was clearly reduced. (j) Quantification of positive neurons in the dentate nucleus revealed a significant reduction of ZIC4-positive neurons in patients with either mixed subtype (light blue) or OPCA (dark blue) compared to SND or controls without neurodegenerative disease, while no difference was seen between patients with SND and healthy controls. Scale bars: a-c: 100 µm, d-f: 200 µm, g-i: 50 µm

Discussion

As part of the study, brain banks were contacted worldwide and all available caucasian MSA brains were included. As in the prior GWAS with 918 predominantly clinically diagnosed MSA patients, our current GWAS of 648 autopsy-confirmed MSA patients, did not identify disease-associated common variants below the genome-wide significance threshold.

Since our prior GWAS of 219 patients with autopsy-confirmed corticobasal degeneration did identify significant disease-associated common variants, our current findings strongly suggest that the genetic contribution to disease risk is smaller in MSA.[18]

Nevertheless, our study reveals several suggestive associations at different loci, which may provide relevant hypotheses for follow-up investigations into the pathogenesis of MSA.

Specifically, we identified a variant on chromosome 3 (rs16859966, P = 8.6 × 10−7,, OR = 1.58 [1.32-1.89]) located upstream ZIC1 and ZIC4. ZIC1 and ZIC4 are located in close genomic proximity to each other and encode transcription factors highly expressed in different brain areas[1, 38].

Proper function of these proteins is critical for the development of the CNS, particularly the cerebellum.[5] Although no effect of rs16859966 on ZIC1 or ZIC4 expression is recorded in the GTEx database, rare genetic variants or deletions in ZIC1 or ZIC4 result in congenital cerebellar defects.[5, 13, 25] A heterozygous deletion of ZIC1 and ZIC4 causes the Dandy-Walker malformation, a developmental disorder of the cerebellum.[13, 36] Moreover, paraneoplastic autoantibodies against ZIC4 induce cerebellar degeneration.[4] Due to the pronounced cerebellar degeneration in MSA, we followed-up on a possible role of ZIC4 in MSA.

While we could detect a relatively constant proportion of approximately one third ZIC4-positive neurons among all neurons in the cerebellar dentate nucleus in healthy controls and patients with MSA-SND, cases with MSA-OPCA or the mixed MSA phenotype showed significantly lower fractions of ZIC4-positive neurons. This finding suggests that ZIC4 may be involved in the neurodegeneration in MSA. The involvement of ZIC4 mutations in the Dandy-Walker cerebellar malformation and the paraneoplastic ZIC4-autoantibody-associated cerebellar degeneration could suggest a pathomechanism in MSA, by which altered ZIC4 expression could increase neuronal vulnerability. Further analyses of a potential functional interaction of alpha-synuclein and ZIC4 are currently ongoing.

We would like to strongly encourage independent replication studies to confirm or refute the hypotheses provided by our study.

Data Availability

All data produced in the present work are contained in the manuscript

Supplementary Tables

View this table:
  • View inline
  • View popup
Supplementary Table S1: Recruitment centers, brain bank sources
View this table:
  • View inline
  • View popup
  • Download powerpoint
Supplementary Table S2: Summary of per sample quality control. SD = standard deviation.
View this table:
  • View inline
  • View popup
Supplementary Table S3: Summary of per marker quality control. MAF = minor allele frequency, HWE = Hardy-Weinberg equilibrium.
View this table:
  • View inline
  • View popup
Supplementary Table S4: Identified associations with P < 5 × 10−6.

Results from association analysis with logistic regression including sex and the first two dimensions of PCA as covariates in 648 cases with MSA and 2,898 controls. BP = base-pair coordinates according to human reference genome GRCh38, CHR = Chromosome, dbSNP = database of single nucleotide polymorphisms, GT = genotyped, IM = imputed, L95 = Lower bound of 95% confidence interval for odds ratio, MAF = minor allele frequency, U95= Upper bound of 95% confidence interval for odds ratio.

View this table:
  • View inline
  • View popup
Supplementary Table S5: Top Parkinson’s disease SNPs according to the Parkinson’s disease meta-analysis of genome-wide association studies, Nalls et al. 2019.

The SNP selection is based on results from the meta-analysis of 17 datasets from Parkinson’s disease GWAS available from European ancestry samples. BP = base-pair coordinates according to human reference genome GRCh38, CHR = Chromosome, dbSNP = database of single nucleotide polymorphisms, L95 = Lower bound of 95% confidence interval for odds ratio, MAF = minor allele frequency, U95= Upper bound of 95% confidence interval for odds ratio.

Supplementary Figures

Supplementary Fig. S1.
  • Download figure
  • Open in new tab
Supplementary Fig. S1. Flowchart sample quality control. SD = standard deviation.
Supplementary Fig. S2.
  • Download figure
  • Open in new tab
Supplementary Fig. S2. Association plots for genotyped data.

(a) QQ plot based on 477,261 variants. (b) Manhattan plot showing –log10 P-values from logistic regression on genotyped variants with sex and two principal components as covariates plotted against their chromosomal position.

Supplementary Fig. S3.
  • Download figure
  • Open in new tab
Supplementary Fig. S3. Regional plots for further loci with suggestive associations.

(a) Regional plot for associations on chromsome 4 in the genomic region from 30.8 to 32.0 Mb.

(b) Regional plot for associations on chromsome 5 in the genomic region from 159.0 to 160.2 Mb.

(c) Regional plot for associations on chromsome 10 in the genomic region from 84.7 to 85.9 Mb.

(d) Regional plot for associations on chromsome 11 in the genomic region from 47.1 to 48.3 Mb.

(e) Regional plot for associations on chromsome 16 in the genomic region from 79.9 to 81.1 Mb.

(f) Regional plot for associations on chromsome 18 in the genomic region from 30.0 to 31.2 Mb.

Acknowledgements

We would like to thank all those who contributed towards our research, particularly the patients and families who donated brain tissue - without their donation this study would not have been possible. We thank Vanessa Boll and Lena Jaschkowitz for excellent technical assistance.

The study received support from the Deutsche Parkinson Gesellschaft, the Else-Kröner-Fresenius-Stiftung, the CurePSP foundation, the Alzheimer’s Disease Genetics Consortium (ADGC) NIA grant U01AG032984, the National Alzheimer’s Coordinating Center (NACC) NIA grant U01 AG016976 and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198), the Hannover Cluster RESIST (EXC 2155 – ID 390874280) and the Kiel Cluster (EXC2167, Precision Medicine in Chronic Inflammation (PMI)), the DFG grant (HO2402/18-1), the VolkswagenStiftung (Niedersächsisches Vorab), the Petermax-Müller Foundation (Etiology and Therapy of Synucleinopathies and Tauopathies), and ERARE18-124 (MSA-omics) under the frame of E-Rare-3, the ERA-Net for Research on Rare Diseases.

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (NIA grant U24-AG041689).

Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible;

A part of the samples was collected at the Mayo Clinic. The Mayo Clinic is an American Parkinson Disease Association (APDA) Mayo Clinic Information and Referral Center, an APDA Center for Advanced Research, and is supported by a Lewy Body Dementia Center Without Walls U54NS110435 (to D.W.D. & O.A.R.). The brain bank was supported, in part, by the Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic.

The London Neurodegenerative Diseases Brain Bank, King’s College London is supported by the MRC (Medical Research Council, UK) and the Brains for Dementia Research project (jointly funded by the Alzheimer’s Society and Alzheimer’s Research UK).

Data were contributed to this study by the Center on Alpha-synuclein Strains in Alzheimer Disease & Related Dementias at the University of Pennsylvania Perelman School of Medicine (U19 AG062418, Trojanowski JQ-PI) and the former Morris K. Udall Center at the University of Pennsylvania Perelman School of Medicine (P50 NS053488, Trojanowski JQ-PI), NIA P01-AG066597 and AG072979 (formerly AG010124).

References

  1. ↵
    Ali RG, Bellchambers HM, Arkell RM (2012) Zinc fingers of the cerebellum (Zic): transcription factors and co-factors. Int J Biochem Cell Biol 44: 2065–2068 Doi 10.1016/j.biocel.2012.08.012
    OpenUrlCrossRefPubMed
  2. ↵
    Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, Donnelly P, Eichler EE et al. (2015) A global reference for human genetic variation. Nature 526: 68–74 Doi 10.1038/nature15393
    OpenUrlCrossRefPubMed
  3. ↵
    Bataller L, Wade DF, Fuller GN, Rosenfeld MR, Dalmau J (2002) Cerebellar degeneration and autoimmunity to zinc-finger proteins of the cerebellum. Neurology 59: 1985–1987 Doi 10.1212/01.wnl.0000038352.01415.ce
    OpenUrlCrossRef
  4. ↵
    Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J (2004) Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62: 778–782 Doi 10.1212/01.wnl.0000113749.77217.01
    OpenUrlCrossRefPubMed
  5. ↵
    Blank MC, Grinberg I, Aryee E, Laliberte C, Chizhikov VV, Henkelman RM, Millen KJ (2011) Multiple developmental programs are altered by loss of Zic1 and Zic4 to cause Dandy-Walker malformation cerebellar pathogenesis. Development 138: 1207–1216 Doi 10.1242/dev.054114
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Brown DW, Myers TA, Machiela MJ (2020) PCAmatchR: a flexible R package for optimal case–control matching using weighted principal components. Bioinformatics 37: 1178–1181 Doi 10.1093/bioinformatics/btaa784
    OpenUrlCrossRef
  7. ↵
    Chen Y, Wei QQ, Ou R, Cao B, Chen X, Zhao B, Guo X, Yang Y, Chen K, Wu Y et al. (2015) Genetic Variants of SNCA Are Associated with Susceptibility to Parkinson’s Disease but Not Amyotrophic Lateral Sclerosis or Multiple System Atrophy in a Chinese Population. PLoS One 10: e0133776 Doi 10.1371/journal.pone.0133776
    OpenUrlCrossRef
  8. ↵
    Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF (2004) Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 23: 201–208 Doi 10.1159/000078506
    OpenUrlCrossRefPubMed
  9. ↵
    Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical Methods groups-Analysis Working G, Enhancing Gg, Fund NIHC, Nih/Nci, Nih/Nhgri, Nih/Nimh, Nih/Nida et al. (2017) Genetic effects on gene expression across human tissues. Nature 550: 204–213 Doi 10.1038/nature24277
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning GK (2019) Multiple system atrophy. Int Rev Neurobiol 149: 137–192 Doi 10.1016/bs.irn.2019.10.004
    OpenUrlCrossRef
  11. ↵
    Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372: 249–263 Doi 10.1056/NEJMra1311488
    OpenUrlCrossRefPubMed
  12. ↵
    Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670–676 Doi 10.1212/01.wnl.0000324625.00404.15
    OpenUrlCrossRefPubMed
  13. ↵
    Grinberg I, Northrup H, Ardinger H, Prasad C, Dobyns WB, Millen KJ (2004) Heterozygous deletion of the linked genes ZIC1 and ZIC4 is involved in Dandy-Walker malformation. Nat Genet 36: 1053–1055 Doi 10.1038/ng1420
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Jellinger KA, Lantos PL (2010) Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 119: 657–667 Doi 10.1007/s00401-010-0672-3
    OpenUrlCrossRefPubMed
  15. ↵
    Jellinger KA, Seppi K, Wenning GK (2005) Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20 Suppl 12: S29–36 Doi 10.1002/mds.20537
    OpenUrlCrossRefPubMed
  16. ↵
    Klockgether T, Ludtke R, Kramer B, Abele M, Burk K, Schols L, Riess O, Laccone F, Boesch S, Lopes-Cendes I et al. (1998) The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 121 (Pt 4): 589–600 Doi 10.1093/brain/121.4.589
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85: 404–412 Doi 10.1212/WNL.0000000000001807
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NCA, Yoon H, Kim J et al. (2015) Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 6: 7247 Doi 10.1038/ncomms8247
    OpenUrlCrossRefPubMed
  19. ↵
    Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A et al. (2019) Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51: 414–430 Doi 10.1038/s41588-019-0358-2
    OpenUrlCrossRefPubMed
  20. ↵
    Labbe C, Heckman MG, Lorenzo-Betancor O, Murray ME, Ogaki K, Soto-Ortolaza AI, Walton RL, Fujioka S, Koga S, Uitti RJ et al. (2016) MAPT haplotype diversity in multiple system atrophy. Parkinsonism Relat Disord 30: 40–45 Doi 10.1016/j.parkreldis.2016.06.010
    OpenUrlCrossRef
  21. ↵
    Labbe C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A et al. (2015) Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies. Neurology 85: 1680–1686 Doi 10.1212/WNL.0000000000001946
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A et al. (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18: 1091–1102 Doi 10.1016/S1474-4422(19)30320-5
    OpenUrlCrossRef
  23. ↵
    Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ (1991) Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1: 9–13 Doi 10.1007/bf01826052
    OpenUrlCrossRefPubMed
  24. ↵
    Nothlings U, Krawczak M (2012) [PopGen. A population-based biobank with prospective follow-up of a control group]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55: 831–835 Doi 10.1007/s00103-012-1487-2
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Ogura H, Aruga J, Mikoshiba K (2001) Behavioral abnormalities of Zic1 and Zic2 mutant mice: implications as models for human neurological disorders. Behav Genet 31: 317–324 Doi 10.1023/a:1012235510600
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, Healy DG, Wood NW, Lees AJ, Holton JL et al. (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127: 2657–2671 Doi 10.1093/brain/awh303
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ (2010) LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26: 2336–2337 Doi 10.1093/bioinformatics/btq419
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Rohrer G, Hoglinger GU, Levin J (2018) Symptomatic therapy of multiple system atrophy. Auton Neurosci 211: 26–30 Doi 10.1016/j.autneu.2017.10.006
    OpenUrlCrossRef
  29. ↵
    Ronchi D, Di Biase E, Franco G, Melzi V, Del Sorbo F, Elia A, Barzaghi C, Garavaglia B, Bergamini C, Fato R et al. (2016) Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiol Aging 45: 213 e211–213 e212 Doi 10.1016/j.neurobiolaging.2016.05.022
    OpenUrlCrossRef
  30. ↵
    Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K et al. (2016) A genome-wide association study in multiple system atrophy. Neurology 87: 1591–1598 Doi 10.1212/WNL.0000000000003221
    OpenUrlCrossRefPubMed
  31. ↵
    Schottlaender LV, Houlden H, Multiple-System Atrophy Brain Bank C (2014) Mutant COQ2 in multiple-system atrophy. N Engl J Med 371: 81 Doi 10.1056/NEJMc1311763
    OpenUrlCrossRef
  32. ↵
    Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y (2008) Survival in multiple system atrophy. Mov Disord 23: 294–296 Doi 10.1002/mds.21839
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41: 1308–1312 Doi 10.1038/ng.487
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG, Corvelo A, Gogarten SM, Kang HM et al. (2021) Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590: 290–299 Doi 10.1038/s41586-021-03205-y
    OpenUrlCrossRefPubMed
  35. ↵
    Team RC (2019) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing V, Austria.
  36. ↵
    Tohyama J, Kato M, Kawasaki S, Harada N, Kawara H, Matsui T, Akasaka N, Ohashi T, Kobayashi Y, Matsumoto N (2011) Dandy-Walker malformation associated with heterozygous ZIC1 and ZIC4 deletion: Report of a new patient. Am J Med Genet A 155A: 130–133 Doi 10.1002/ajmg.a.33652
    OpenUrlCrossRef
  37. ↵
    Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33: 615–620 Doi 10.1111/j.1365-2990.2007.00907.x
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A et al. (2015) Proteomics. Tissue-based map of the human proteome. Science 347: 1260419 Doi 10.1126/science.1260419
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, Stocchi F, Nicholl D, Bonuccelli U, De Mari M et al. (2005) Case-control study of multiple system atrophy. Mov Disord 20: 158–163 Doi 10.1002/mds.20303
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O et al. (2018) Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology 90: 74–82 Doi 10.1212/WNL.0000000000004798
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Kollensperger M, Goebel G, Pfeiffer KP, Barone P et al. (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12: 264–274 Doi 10.1016/S1474-4422(12)70327-7
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Wichmann HE, Gieger C, Illig T, Group MKS (2005) KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67 Suppl 1: S26–30 Doi 10.1055/s-2005-858226
    OpenUrlCrossRefPubMedWeb of Science
Back to top
PreviousNext
Posted November 12, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genome-wide association study of autopsy-confirmed Multiple System Atrophy identifies common variants near ZIC1 and ZIC4
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genome-wide association study of autopsy-confirmed Multiple System Atrophy identifies common variants near ZIC1 and ZIC4
Franziska Hopfner, Anja K. Tietz, Viktoria Ruf, Owen A. Ross, Shunsuke Koga, Dennis Dickson, Adriano Aguzzi, Johannes Attems, Thomas Beach, Allison Beller, Vivianna van Deerlin, Paula Desplats, Günther Deuschl, Charles Duyckaerts, David Ellinghaus, Valentin Evsyukov, Margaret Ellen Flanagan, Andre Franke, Matthew P. Frosch, Marla Gearing, Ellen Gelpi, Bernardino Ghetti, Jonathan D. Glass, Lea T. Grinberg, Glenda Halliday, Ingo Helbig, Matthias Höllerhage, Inge Huitinga, David John Irwin, Dirk C. Keene, Gabor G. Kovacs, Edward B. Lee, Johannes Levin, Maria J. Martí, Ian Mackenzie, Ian McKeith, Catriona Mclean, Brit Mollenhauer, Manuela Neumann, Kathy L. Newell, Alex Pantelyat, Manuela Pendziwiat, Annette Peters, Laura Molina Porcel, Alberto Rabano, Radoslav Matěj, Alex Rajput, Ali Rajput, Regina Reimann, William K. Scott, William Seeley, Sashika Selvackadunco, Tanya Simuni, Christine Stadelmann, Per Svenningsson, Alan Thomas, Claudia Trenkwalder, Claire Troakes, John Q. Trojanowski, Charles L. White, Tao Xie, Teresa Ximelis, Justo Yebenes, the Alzheimer’s Disease Genetics Consortium, Ulrich Müller, Gerard D. Schellenberg, Jochen Herms, Gregor Kuhlenbäumer, Günter Höglinger
medRxiv 2021.11.11.21265915; doi: https://doi.org/10.1101/2021.11.11.21265915
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Genome-wide association study of autopsy-confirmed Multiple System Atrophy identifies common variants near ZIC1 and ZIC4
Franziska Hopfner, Anja K. Tietz, Viktoria Ruf, Owen A. Ross, Shunsuke Koga, Dennis Dickson, Adriano Aguzzi, Johannes Attems, Thomas Beach, Allison Beller, Vivianna van Deerlin, Paula Desplats, Günther Deuschl, Charles Duyckaerts, David Ellinghaus, Valentin Evsyukov, Margaret Ellen Flanagan, Andre Franke, Matthew P. Frosch, Marla Gearing, Ellen Gelpi, Bernardino Ghetti, Jonathan D. Glass, Lea T. Grinberg, Glenda Halliday, Ingo Helbig, Matthias Höllerhage, Inge Huitinga, David John Irwin, Dirk C. Keene, Gabor G. Kovacs, Edward B. Lee, Johannes Levin, Maria J. Martí, Ian Mackenzie, Ian McKeith, Catriona Mclean, Brit Mollenhauer, Manuela Neumann, Kathy L. Newell, Alex Pantelyat, Manuela Pendziwiat, Annette Peters, Laura Molina Porcel, Alberto Rabano, Radoslav Matěj, Alex Rajput, Ali Rajput, Regina Reimann, William K. Scott, William Seeley, Sashika Selvackadunco, Tanya Simuni, Christine Stadelmann, Per Svenningsson, Alan Thomas, Claudia Trenkwalder, Claire Troakes, John Q. Trojanowski, Charles L. White, Tao Xie, Teresa Ximelis, Justo Yebenes, the Alzheimer’s Disease Genetics Consortium, Ulrich Müller, Gerard D. Schellenberg, Jochen Herms, Gregor Kuhlenbäumer, Günter Höglinger
medRxiv 2021.11.11.21265915; doi: https://doi.org/10.1101/2021.11.11.21265915

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8550)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1744)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10281)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1670)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (247)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1764)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (520)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)